Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. (Nasdaq: ENSC) is a clinical-stage pharmaceutical company focused on the development of abuse-deterrent drug formulations and drug delivery technologies targeting opioid misuse. The company entered public markets through a SPAC business combination in the biopharmaceutical sector, with an 8-K filed on June 30, 2020 representing a material disclosure tied to that process. Ensysce's programs are designed to deter common methods of prescription drug abuse, positioning the company within the specialty pharmaceuticals and addiction-treatment space. Sign up at SpacDesk for full transaction records, sponsor details, filing timelines, and deal analytics on Ensysce Biosciences and thousands of other SPAC transactions.